Immunotherapy in Melanoma | Specialty

BRAF/MEK Dual-Targeted Therapy in Advanced Melanoma

March 28th 2019

Addressing Challenges With BRAF Inhibitors in Melanoma

March 28th 2019

BRAF as a Driver in Melanoma

March 28th 2019

Melanoma as an Oncogene-Addicted Cancer

March 28th 2019

Gene Mutations in Melanoma

March 28th 2019

Childhood Cancer Survivors at Increased Risk for Skin Cancers

March 26th 2019

Childhood cancer survivors who had lived 5 or more years from their primary malignancy are at an increased risk of developing skin cancer compared with the general population.

Dr. Olszanski on Patient Selection for Cemiplimab Treatment in CSCC

March 24th 2019

Anthony J. Olszanski, MD, RPh, discusses the treatment selection process for use of cemiplimab in patients with cutaneous squamous cell carcinoma.

SITC Guidelines Provide a Fresh Look at Evolving Strategies for Melanoma

March 14th 2019

New therapeutic approaches for treating patients with earlier-stage melanoma who face a higher risk of recurrence are among the features of recently updated consensus guidelines from the Society for Immunotherapy of Cancer.

EU Panel Backs Extended Pembrolizumab Dosing Schedule for Single-Agent Indications

March 5th 2019

The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion for a new extended dosing schedule for pembrolizumab for all of the PD-1 inhibitor’s monotherapy indications in the European Union.

New Targeted Therapy Duo Provides Advantages in BRAF-Mutant Melanoma

March 4th 2019

Keith T. Flaherty, MD, discussed the distinguishing features of the combination of encorafenib with binimetinib as well as some next steps, including the question of whether the regimen eventually could move to the adjuvant setting.

Dr. Sullivan on Considerations for Treatment in Metastatic Melanoma

February 28th 2019

Ryan J. Sullivan, MD, instructor of Medicine, Harvard Medical School, assistant in medicine, MGH Cancer Center, Massachusetts General Hospital, discusses considerations for initial treatment of patients with metastatic melanoma.

Diet May Impact Response to Immunotherapy in Patients With Melanoma

February 28th 2019

Select patients with melanoma who consume a diet rich in fiber could see an improved response to treatment with immunotherapy.

Dr. Ribas on Immune-Related Adverse Events in Melanoma

February 27th 2019

Antoni Ribas, MD, PhD, professor of medicine, University of California, Los Angeles, director, Tumor Immunology Program, Jonsson Comprehensive Cancer Center, discusses immune-related adverse events (irAEs) in melanoma.

Dr. Tawbi on Unmet Needs in Melanoma

February 22nd 2019

Hussein A. Tawbi, MD, PhD, associate professor, The University of Texas MD Anderson Cancer Center, discusses unmet needs in melanoma.

Dr. Weber on FDA Approval of Pembrolizumab for Stage III Melanoma

February 19th 2019

Jeffrey S. Weber, MD, PhD, deputy director and co-director of the Melanoma Program, NYU Langone's Perlmutter Cancer Center, a 2016 Giant of Cancer Care in Melanoma, discusses the FDA approval of pembrolizumab for stage III melanoma.

FDA Approves Adjuvant Pembrolizumab in Stage III Melanoma

February 19th 2019

The FDA has approved the PD-1 inhibitor pembrolizumab for the adjuvant treatment of patients with high-risk stage III melanoma with lymph node involvement following complete resection.

Dr. Triebel on the Rationale for a Novel Immunotherapy Combination in Melanoma

January 30th 2019

Frederic Triebel, MD, PhD, chief scientific officer and chief medical director, Immutep Ltd, discusses the rationale for a novel immunotherapy combination in patients with unresectable or metastatic melanoma.

Dr. Ribas on Combination Immunotherapy and Radiation in Melanoma

January 22nd 2019

Antoni Ribas, MD, PhD, professor of medicine, University of California, Los Angeles, director, Tumor Immunology Program, Jonsson Comprehensive Cancer Center, discusses the potential for combination immunotherapy and radiation in the treatment of patients with melanoma.

Pembrolizumab Granted 5 Additional Approvals in Japan

January 3rd 2019

The Japan Pharmaceuticals and Medical Devices Agency has approved pembrolizumab for 5 new indications, including melanoma, advanced microsatellite instability-high tumors, and 3 expanded uses in advanced non–small cell lung cancer.

Dr. Hamid on the FDA Approval of Pembrolizumab in Merkel Cell Carcinoma

December 20th 2018

Omid Hamid, MD, director of Research and Immuno-Oncology at The Angeles Clinic, discusses the FDA approval of pembrolizumab (Keytruda) for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma.